Investigational Herpes Drug Limits Viral Shedding in Phase II Trial (FREE)

By Kelly Young Pritelivir, the first in a new class of drugs (a helicase-primase inhibitor) for herpes simplex virus, effectively suppressed viral shedding and development of genital lesions in an industry-conducted, phase II …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news